Colchicine for heart health after a heart attack
Treatments studied
Part of Blood & lymphatic, Heart & circulation clinical trials.
This study tests whether a low-dose medicine called colchicine can reduce inflammation and slow down artery blockages in people who have a specific gene change (TET2) and have recently had a heart attack. The goal is to see if it helps prevent future heart problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 85 years old.
- You had a heart attack or unstable angina 30 to 90 days ago.
- During that hospital stay, you had a stent placed or just an angiogram.
- You have at least one partially blocked artery (30% to 70% narrowed).
- You have a gene change called TET2-CHIP or no CHIP, confirmed by a blood test.
- You are not taking colchicine now and are not allergic to it.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a low dose of the anti-inflammatory drug colchicine can help people who have recently had a heart attack or unstable angina. It aims to see if colchicine reduces the risk of future heart problems.
This trial tests whether taking a low dose of colchicine, an anti-inflammatory medicine, after heart bypass surgery can help keep the new blood vessels open and working well. It may help reduce the chance of the bypass grafts failing.
This trial tests if colchicine, an anti-inflammatory medicine, can help people who recently had a heart attack. It looks for markers in your blood to see who might benefit most.
This trial tests whether colchicine (a medicine commonly used for inflammation) can improve how well clogged heart arteries reopen after a short-term heart emergency called ACS. You may be eligible if you’re hospitalized with ACS and are planned for a coronary angiogram and possible angioplasty soon.
This trial tests if colchicine, a common anti-inflammatory medicine, can help prevent future heart problems in people who have coronary artery disease and recently had a stent placed. It's for adults with at least one extra risk factor like diabetes, smoking, or high blood pressure.
This trial is for people who had a heart attack and received a specific type of stent (Orsiro). It tests a combination of a single antiplatelet drug and colchicine to see if it helps prevent future heart problems. Colchicine is a medicine that reduces inflammation and might lower the risk of another heart attack.
Hear when a new Colchicine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.